Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This multicenter phase II trial is designed to study the unique combination of chemotherapy
(irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical
setting seems ideal for evaluation of the role of bevacizumab in delaying progression and
prolonging survival.